+ Watch MNKD
on My Watchlist
A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.
There's no point in going over what's been argued a million times. At this price level, I see more downside in the short-term regardless of the PDUFA outcome. I think another technical CRL is the most likely verdict, but I'm far from sure that's what will happen.The main long-term issue, as always, is whether inhaled insulin represents a genuine improvement over injected insulin. The FDA has certainly questioned this in the past, and I've yet to meet a diabetic who didn't take his insulin because of fear of needles.I haven't been wrong yet on Mannkind (my one negative score would have turned positive quickly if I hadn't chickened out) and a significant pullback here might give me score leadership. Then you'll have to put up with whatever I have to say about this company, and no reply button.
I guess we see different types of diabetic patients. I know a lot of diabetics who should be taking insulin but aren't because of the fear of needles. That you haven't yet met a single one of these patients is impressive or surprising... Do you talk to them?Many of the patients I see are also scared of hypoglycemia and weight gain. Afrezza seems to be better at that then injected insulin. Do any of your patients worry about those things? I presume not since you practice medicine in a tough area I guess. An old endocrinologist told me Afrezza is for whimps. He tells his patients: 'take your needles like a man' or something to that effect. You guys would get along well I guess! Scared of needles, weight gain and hypoglycemia? Be a whimp and go for Afrezza!
GO BABY GO!!!
dig'n it Baby. My call option are through the roooof.Go BB Go is right.Question is...do I hold the Jan options with THE decision still looming??
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions